Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives

References

• Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J. 27(8), 949–953 (2006).
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18), 2370–2375 (2001).
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22(8), 983–988 (1991).
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146(12), 857–867 (2007).
   PubMed Web of Science ®Google Scholar
• Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). Stroke 37(8), 1969–1974 (2006).
   PubMed Web of Science ®Google Scholar
• Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 4(1), 14–21 (2011).
   PubMed Web of Science ®Google Scholar
• Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am. J. Med. 123(7), 638–645.e4 (2010).
   PubMed Web of Science ®Google Scholar
• van Walraven C, Hart RG, Connolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 40(4), 1410–1416 (2009).
   PubMed Web of Science ®Google Scholar
• Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 349(11), 1019–1026 (2003).
   PubMed Web of Science ®Google Scholar
• Indredavik B, Rohweder G, Lydersen S. Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation. J. Intern. Med. 258(2), 133–144 (2005).
   Google Scholar
• Gladstone DJ, Bui E, Fang J et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40(1), 235–240 (2009).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Eikelboom J et al.; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118(20), 2029–2037 (2008).
   PubMed Web of Science ®Google Scholar
• Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154, 1449–1457 (1994).
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J. Stroke Cerebrovasc. Dis. 5, 147–157 (1995).
   PubMedGoogle Scholar
• Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann. Intern. Med. 28, 639–647 (1998).
   Google Scholar
• Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22), 2864–2870 (2001).
   PubMed Web of Science ®Google Scholar
• Desk R, Williams L, Health K. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 39, 1901–1910 (2008).
   Google Scholar
• Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 37(9), 2294–2300 (2006).
   PubMed Web of Science ®Google Scholar
• Fang MC, Singer DE, Chang Y et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 112(12), 1687–1691 (2005).
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE; ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J. Am. Coll. Cardiol. 51(8), 810–815 (2008).
   PubMed Web of Science ®Google Scholar
• Gage BF, van Walraven C, Pearce L et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110(16), 2287–2292 (2004).
   PubMed Web of Science ®Google Scholar
• Singer DE, Albers GW, Dalen JE et al.; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), S546–S592 (2008).
   Google Scholar
• Fuster V, Rydén LE, Cannom DS et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114(7), e257–e354 (2006).
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. Royal College of Physicians, London, UK (2006).
   Google Scholar
• Wang TJ, Massaro JM, Levy D et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 290(8), 1049–1056 (2003).
   PubMed Web of Science ®Google Scholar
• van Walraven C, Hart RG, Wells GA et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch. Intern. Med. 163(8), 936–943 (2003).
   PubMedGoogle Scholar
• Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am. Heart J. 156(1), 57–64 (2008).
   PubMed Web of Science ®Google Scholar
• OlesenJB, LipGY, HansenML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342, D124 (2011).
   PubMed Web of Science ®Google Scholar
• Baruch L, Gage BF, Horrow J et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke 38(9), 2459–2463 (2007).
   PubMed Web of Science ®Google Scholar
• Lip GY. The role of aspirin for stroke prevention in atrial fibrillation. Nat. Rev. Cardiol. 8(10), 602–606 (2011).
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N. Engl. J. Med. 327(20), 1406–1412 (1992).
   PubMed Web of Science ®Google Scholar
• Avenue G. Stroke prevention in atrial fibrillation study. Final results. Circulation 84, 527–539 (1991).
   Google Scholar
• Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69, 546–554 (2007).
   PubMed Web of Science ®Google Scholar
• Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb. Haemost. 99(2), 295–304 (2008).
   PubMed Web of Science ®Google Scholar
• Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch. Intern. Med. 158, 1316–1320 (1998).
   Google Scholar
• Aronow WS, Ahn C, Kronzon I, Gutstein H. Risk factors for new thromboembolic stroke in patients > or = 62 years of age with chronic atrial fibrillation. Am. J. Cardiol. 82(1), 119–121 (1998).
   Web of Science ®Google Scholar
• Marinigh R, Lip GYH, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation. JACC 56, 827–837 (2011).
   Google Scholar
• Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 30(6), 1223–1229 (1999).
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin J. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. JACC 35, 183–187 (2000).
   Google Scholar
• Cabin HS, Clubb KS, Hall C, Perlmutter RA, Feinstein AR. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am. J. Cardiol. 65(16), 1112–1116 (1990).
   PubMed Web of Science ®Google Scholar
• Inoue H, Atarashi H; Research Group for Antiarrhythmic Drug Therapy. Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation. Am. J. Cardiol. 86(8), 852–855 (2000).
   Google Scholar
• SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 279, 1273–1277 (1998).
   PubMed Web of Science ®Google Scholar
• Lane DA, Lip GY. Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thromb. Haemost. 101(5), 802–805 (2009).
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Lane DA et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am. J. Med. 125(8), 826.e13–826.e23 (2012).
   PubMed Web of Science ®Google Scholar
• Rasmussen LH, Larsen TB, Due KM, Tjønneland A, Overvad K, Lip GY. Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study. J. Thromb. Haemost. 9(7), 1301–1307 (2011).
   PubMed Web of Science ®Google Scholar
• Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GY. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 141(1), 147–153 (2012).
   PubMed Web of Science ®Google Scholar
• Lin LY, Lee CH, Yu CC et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation – a nation wide database analysis. Atherosclerosis 217(1), 292–295 (2011).
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137(2), 263–272 (2010).
   PubMed Web of Science ®Google Scholar
• Altman DG, Royston P. What do we mean by validating a prognostic model? Stat. Med. 19(4), 453–473 (2000).
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur. Heart J. 33(12), 1500–1510 (2012).
   PubMed Web of Science ®Google Scholar
• Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. Thromb. Haemost. 107(6), 1172–1179 (2012).
   PubMed Web of Science ®Google Scholar
• van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J. Thromb. Haemost. 9(1), 39–48 (2011).
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 41(12), 2731–2738 (2010).
   PubMed Web of Science ®Google Scholar
• Hobbs FD, Roalfe AK, Lip GY, Fletcher K, Fitzmaurice DA, Mant J; Birmingham Atrial Fibrillation in the Aged Investigators and Midland Research Practices Consortium Network. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ 342, d3653 (2011).
   Google Scholar
• Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY. Reliable identification of ‘truly low’ thromboembolic risk in patients initially diagnosed with ‘lone’ atrial fibrillation: the Belgrade atrial fibrillation study. Circ. Arrhythm. Electrophysiol. 5(2), 319–326 (2012).
   PubMed Web of Science ®Google Scholar
• Poli D, Lip GY, Antonucci E, Grifoni E, Lane D. Stroke risk stratification in a ‘real-world’ elderly anticoagulated atrial fibrillation population. J. Cardiovasc. Electrophysiol. 22(1), 25–30 (2011).
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Lindhardsen J et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb. Haemost. 106(4), 739–749 (2011).
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125(19), 2298–2307 (2012).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139–1151 (2009).
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125(5), 669–676 (2012).
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883–891 (2011).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364(9), 806–817 (2011).
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981–992 (2011).
   PubMed Web of Science ®Google Scholar
• You JJ, Singer DE, Howard PA et al.; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2), e531S–e575S (2012).
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GY et al.; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31(19), 2369–2429 (2010).
   PubMed Web of Science ®Google Scholar
• Stott DJ, Dewar RI, Garratt CJ et al.; Royal College of Physicians of Edinburgh. RCPE UK Consensus Conference on ‘Approaching the comprehensive management of atrial fibrillation: evolution or revolution?’ J. R. Coll. Physicians Edinb. (42 Suppl. 18), 3–4 (2012).
   Google Scholar
• Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can. J. Cardiol. 27(1), 74–90 (2011).
   PubMed Web of Science ®Google Scholar
• Skanes AC, Healey JS, Cairns JA et al.; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can. J. Cardiol. 28(2), 125–136 (2012).
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R et al.; Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 33(21), 2719–2747 (2012).
   PubMed Web of Science ®Google Scholar
• Hansen ML, Sørensen R, Clausen MT et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch. Intern. Med. 170(16), 1433–1441 (2010).
   PubMed Web of Science ®Google Scholar
• Devereaux PJ, Anderson DR, Gardner MJ et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 323(7323), 1218–1222 (2001).
   PubMed Web of Science ®Google Scholar
• Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb. Haemost. 107(3), 584–589 (2012).
   PubMed Web of Science ®Google Scholar